Ravnborg, Mads <br/><br/>
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.  [electronic resource] 

 -  The Lancet. Neurology  Jul 2010 
 - 672-80 p.  digital 
<br/><br/> Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1474-4465 
<br/><br/><label>Standard No.: </label>10.1016/S1474-4422(10)70132-0  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adjuvants, Immunologic--therapeutic use<br/>Adult<br/>Disability Evaluation<br/>Double-Blind Method<br/>Drug Therapy, Combination--methods<br/>Female<br/>Humans<br/>Interferon beta-1a<br/>Interferon-beta--therapeutic use<br/>Kaplan-Meier Estimate<br/>Longitudinal Studies<br/>Male<br/>Methylprednisolone--therapeutic use<br/>Middle Aged<br/>Multiple Sclerosis, Relapsing-Remitting--drug therapy<br/>Neuroprotective Agents--therapeutic use<br/>Severity of Illness Index<br/>Treatment Outcome